Company Overview and News

13
Cellectar Announces 1-for-10 Reverse Stock Split

2018-07-13 globenewswire
MADISON, Wis., July 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces a 1-for-10 reverse split of its common stock, effective at the close of business today.
CLRB CLRBZ CLRBW

12
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-07-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________
CLRB

19
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-07-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________
CLRB

12
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma

2018-07-09 globenewswire
MADISON, Wis., July 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of Ewing’s sarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

23
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-06-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMI
CLRB

57
Cue Biopharma Strengthens Board of Directors with Addition of Fred Driscoll to Chair Audit Committee

2018-06-28 globenewswire
CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today the addition of Fred Driscoll to the Company’s Board of Directors. Mr. Driscoll is an industry leader with more than 20 years of experience providing financial management and guidance for corporate development and shareholder value creation within the life sciences industry.
CYNA FLXN CLRB CUE MEIP CLRBZ CLRBW

17
Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial

2018-06-28 globenewswire
MADISON, Wis., June 28, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announces that the company will expand patient enrollment in the diffuse large b-cell lymphoma (DLBCL) cohort of its currently enrolling Phase 2 clinical trial of CLR 131.
CLRB CLRBZ CLRBW

89
Your Daily Pharma Scoop: Secondary Offering Review, Week Of June 8-15, VSTM, SRRA

2018-06-19 seekingalpha
Welcome to another week of secondary offering review. Like we have said before, secondary offerings are often a good time to enter into a stock. If a company has otherwise solid credentials but goes down on the offering, that's a good entry point, other things being constant.
GTHX CGEN KTWO VSTM ALPN CLRBZ HTGX CLRBW HTGY HTGZ HTGC CLRB SRRA

25
CLRB / Cellectar Biosciences, Inc. S-1

2018-06-15 sec.gov
As filed with the Securities and Exchange Commission on June 15, 2018 Registration No. 333- &
CLRB

53
CLRB / Cellectar Biosciences, Inc. DEF 14A

2018-06-11 sec.gov
UNITED STATES SE
CLRB

244
Your Daily Pharma Scoop: Aduro Biotech Moves Ahead, MannKind Up, Chimerix Dips

2018-06-11 seekingalpha
Aduro Biotech Inc. (ADRO) is a smallcap with a market capitalization of $533.397M. The company develops immunotherapy drugs, focuses on development of therapies that treat challenging diseases. The Berkeley, CA based company was founded as Oncologic, Inc. in 2000 and renamed to Aduro BioTech, Inc. in June 2008.
MNKD SCD IRWD CMRX TRXC K CLRBZ CLRBW OPHT ADRO FGEN JNJ IOVA LPCN CLRB PFE BMY

91
Your Daily Pharma Scoop: Scynexis Moves Up, Proteostasis Disappoints Investors, Cellectar Zooms

2018-06-11 seekingalpha
Scynexis (NASDAQ:SCYX) is a drug manufacturer focusing on infectious diseases and has $83.85M in market capitalization. The company’s lead candidate SCY-078 is on trial for treatment of multiple serious fungal infections. Some of these fungal infections like Acute Vulvovaginal Candidiasis, Invasive Candidiasis and Invasive Aspergillosis Combo are difficult to treat and can turn into life-threatening conditions.
REGN MYO GSK ZTS CLRB GSK CLRBZ PRPO CLRBW PTI SCYX

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

CUSIP: 15117F302